193 related articles for article (PubMed ID: 36196725)
1. Psoriasis patients' characteristics associated with high PASI response to tildrakizumab: an international dual center study.
Burlando M; Maul JT; Salvi I; Simic D; Cozzani E; Ak M; Birkenmaier I; Parodi A
Eur Rev Med Pharmacol Sci; 2022 Sep; 26(18):6772-6776. PubMed ID: 36196725
[TBL] [Abstract][Full Text] [Related]
2. Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients.
Drerup KA; Seemann C; Gerdes S; Mrowietz U
Dermatology; 2022; 238(4):615-619. PubMed ID: 34775387
[TBL] [Abstract][Full Text] [Related]
3. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis).
Narcisi A; Valenti M; Gargiulo L; Ibba L; Amoruso F; Argenziano G; Bardazzi F; Burlando M; Carrera CG; Damiani G; Dapavo P; Dini V; Franchi C; Girolomoni G; Guarneri C; Loconsole F; Sampogna F; Travaglini M; Malagoli P; Costanzo A
J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):93-103. PubMed ID: 36156312
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1).
Igarashi A; Nakagawa H; Morita A; Okubo Y; Sano S; Imafuku S; Tada Y; Honma M; Mendelsohn AM; Kawamura M; Ohtsuki M
J Dermatol; 2021 Jun; 48(6):853-863. PubMed ID: 33630387
[TBL] [Abstract][Full Text] [Related]
5. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials.
Blauvelt A; Sofen H; Papp K; Gooderham M; Tyring S; Zhao Y; Lowry S; Mendelsohn A; Parno J; Reich K
J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):2305-2312. PubMed ID: 31407394
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.
Reich K; Warren RB; Iversen L; Puig L; Pau-Charles I; Igarashi A; Ohtsuki M; Falqués M; Harmut M; Rozzo S; Lebwohl MG; Cantrell W; Blauvelt A; Thaçi D
Br J Dermatol; 2020 Mar; 182(3):605-617. PubMed ID: 31218661
[TBL] [Abstract][Full Text] [Related]
7. Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study.
Caldarola G; Galluzzo M; Bernardini N; Calabrese L; Grimaldi M; Moretta G; Pagnanelli G; Shumak RG; Talamonti M; Tofani L; Pallotta S; Peris K; Potenza C; De Simone C; Campione E
Dermatol Ther; 2022 Jun; 35(6):e15488. PubMed ID: 35384168
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.
Berenguer-Ruiz S; Aparicio-Domínguez M; Herranz-Pinto P; Ruíz-Villaverde R; López-Ferrer A; Santos-Juanes J; Rodríguez Fernández-Freire L; Hospital-Gil M; Arias-Santiago S; Carretero-Hernández G; Mateu-Puchades A; Ferran M; Del Alcázar E; Santos-Alarcón S; Garcia-Latasa de Aranibar FJ; Belinchón-Romero I; González-Cantero Á; Ruíz-Genao D; Eiris-Salvado N; Rocamora-Durán V; Rivera-Diaz R; de la Cueva P; Daudén E; Salgado-Boquete L; Llamas-Velasco M;
J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):2517-2525. PubMed ID: 37625815
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate-to-severe chronic plaque psoriasis.
Poulin Y; Ramon M; Rosoph L; Weisman J; Mendelsohn AM; Parno J; Rozzo SJ; Lee P
J Eur Acad Dermatol Venereol; 2020 Jul; 34(7):1500-1509. PubMed ID: 31919889
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1).
Imafuku S; Nakagawa H; Igarashi A; Morita A; Okubo Y; Sano S; Tada Y; Nemoto O; Rozzo SJ; Kawamura M; Ohtsuki M
J Dermatol; 2021 Jun; 48(6):844-852. PubMed ID: 33523513
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28.
Papp KA; Reich K; Blauvelt A; Kimball AB; Gooderham M; Tyring SK; Sinclair R; Thaci D; Li Q; Cichanowitz N; Green S; La Rosa C
J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1098-1106. PubMed ID: 30838709
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis.
Di Brizzi EV; Buononato D; Benvenuto P; Argenziano G; De Pasquale R; Fiorella CS; Giofrè C; Musumeci ML; Palazzo G; Zichichi L; Balato A
Dermatol Pract Concept; 2023 Oct; 13(4):. PubMed ID: 37992389
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis.
Feldman SR; Merola JF; Pariser DM; Zhang J; Zhao Y; Mendelsohn AM; Gottlieb AB
J Dermatolog Treat; 2022 May; 33(3):1670-1675. PubMed ID: 33678106
[TBL] [Abstract][Full Text] [Related]
14. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting.
Burlando M; Castelli R; Cozzani E; Parodi A
Drugs Context; 2021; 10():. PubMed ID: 34104197
[TBL] [Abstract][Full Text] [Related]
15. Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis.
Elewski B; Menter A; Crowley J; Tyring S; Zhao Y; Lowry S; Rozzo S; Mendelsohn AM; Parno J; Gordon K
J Dermatolog Treat; 2020 Dec; 31(8):763-768. PubMed ID: 31268369
[No Abstract] [Full Text] [Related]
16. Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 Weeks.
Ter Haar ELM; Van den Reek JMPA; Gaarn Du Jardin K; Barbero-Castillo A; De Jong EMGJ; Lubeek SFK
Acta Derm Venereol; 2023 Oct; 103():adv17752. PubMed ID: 37877618
[TBL] [Abstract][Full Text] [Related]
17. Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA).
Graier T; Weger W; Jonak C; Sator P; Zikeli C; Prillinger K; Sassmann C; Gruber B; Saxinger W; Ratzinger G; Painsi C; Mlynek A; Häring N; Sadoghi B; Trattner H; Müllegger R; Quehenberger F; Salmhofer W; Wolf P
Sci Rep; 2022 Sep; 12(1):15078. PubMed ID: 36064563
[TBL] [Abstract][Full Text] [Related]
18. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis).
Gargiulo L; Ibba L; Cascio Ingurgio R; Malagoli P; Amoruso F; Balato A; Bardazzi F; Brianti P; Brunasso G; Burlando M; Cagni AE; Caproni M; Carrera CG; Carugno A; Caudullo F; Cuccia A; Dapavo P; Di Brizzi EV; Dini V; Gaiani FM; Gisondi P; Guarneri C; Lasagni C; Licata G; Loconsole F; Marzano AV; Megna M; Mercuri SR; Musumeci ML; Orsini D; Ribero S; Ruffo Di Calabria V; Satolli F; Strippoli D; Travaglini M; Trovato E; Venturini M; Zichichi L; Valenti M; Costanzo A; Narcisi A
J Dermatolog Treat; 2024 Dec; 35(1):2350760. PubMed ID: 38714323
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies.
Kimball AB; Papp KA; Reich K; Gooderham M; Li Q; Cichanowitz N; La Rosa C; Blauvelt A
Br J Dermatol; 2020 Jun; 182(6):1359-1368. PubMed ID: 31487406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
